Abstract
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK inhibitors with BRAF inhibition alone showed increased progression-free survival and reduced incidence of secondary malignancies in patients with mutant BRAF V600 melanoma. This trial provides strong support for developing combinations hitting the same pathway in melanoma.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase II as Topic
-
Humans
-
MAP Kinase Kinase 1 / antagonists & inhibitors*
-
Melanoma / drug therapy*
-
Molecular Targeted Therapy
-
Neoplasms, Second Primary / prevention & control*
-
Prognosis
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Signal Transduction / drug effects*
Substances
-
Antineoplastic Agents
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
MAP Kinase Kinase 1
-
MAP2K1 protein, human